Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer
2002

Breast Cancer and Tamoxifen Resistance

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): Murphy L C, Leygue E, Niu Y, Snell L, Ho S-M, Watson P H

Primary Institution: University of Manitoba

Hypothesis

Altered expression of oestrogen receptor-beta and/or altered relative expression of coactivators and corepressors of oestrogen receptors are associated with and may be mechanisms of de novo tamoxifen resistance in oestrogen receptor positive breast cancer.

Conclusion

The study found that high total oestrogen receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours, suggesting a potential link between oestrogen receptor expression and tamoxifen sensitivity.

Supporting Evidence

  • High total oestrogen receptor beta protein expressors were more frequently observed in tamoxifen sensitive tumours than resistant tumours.
  • No significant differences in the relative expression of oestrogen receptor β2, oestrogen receptor β5 and full-length oestrogen receptor β1 RNA in the tamoxifen sensitive and resistant groups were found.
  • PR levels were significantly higher in the tamoxifen sensitive group compared to the tamoxifen resistant group.

Takeaway

This study looked at breast cancer patients to see if certain proteins could explain why some don't respond to tamoxifen, a common treatment. They found that some patients with more of a specific protein did better with the treatment.

Methodology

The study analyzed primary breast tumours from patients who were either tamoxifen sensitive or resistant, measuring the expression of oestrogen receptor isoforms and coregulators using immunohistochemistry and RT-PCR.

Limitations

The study had a small sample size and limited availability of frozen tissue samples for some analyses.

Participant Demographics

Patients were node negative, primary breast cancer cases, with a median age of 69 years for tamoxifen sensitive and 67 years for tamoxifen resistant groups.

Statistical Information

P-Value

0.046

Statistical Significance

p=0.046

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600654

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication